What do systematic reviews say?

Tramadol in combination with acetaminophen vs placebo

• Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 614 participants
  Moderate

Postoperative systemic antibiotics (phenoxymethylpenicillin/penicillin VK, 7-day course), partial or total chemo-mechanical debridement and analgesics vs Matched placebo, partial or total chemo-mechanical debridement and analgesics

Postoperative systemic antibiotics… showed no clear difference in number of paracetamol (acetaminophen) with codeine tablets required compared with matched placebo, partial or total chemo-mechanical debridement and…; GRADE not reported.

• Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults 2024 · Cochrane All outcomes

  7 days
  MD -0.31 [-3.94, 3.32]
  1 study · 41 participants
  GRADE not reported

Systemic antibiotic (oral penicillin 500 mg) plus analgesic vs Placebo plus analgesic

Systemic antibiotic (oral penicillin 500 mg) plus analgesic showed no clear difference in total number of paracetamol (acetaminophen) with codeine (Tylenol)… compared with placebo plus analgesic (low certainty).

• Antibiotic use for irreversible pulpitis 2019 · Cochrane All outcomes

  7 days
  MD 2.45 [-1.23, 6.13]
  1 study · 40 participants
  Low

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.57, 1.37]
  1 study · 173 participants
  Low

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.19 [0.62, 2.16]
  1 study · 184 participants
  Low

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in liver transplant compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 0.72 [0.49, 1.06]
  1 study · 173 participants
  Low

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.07 [0.79, 1.45]
  1 study · 173 participants
  Low

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.47 [0.85, 2.53]
  1 study · 184 participants
  Low

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.25 [0.35, 4.51]
  1 study · 184 participants
  Low

N‐acetylcysteine vs placebo

N‐acetylcysteine showed no clear difference in liver Transplant compared with placebo (low certainty).

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  RR 1.28 [0.89, 1.84]
  1 study · 184 participants
  Low

Methionine and supportive treatment vs supportive treatment

It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).

• Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
  Peto OR 0.14 [0, 6.82]
  1 study · 26 participants
  Very low

Standard intravenous acetylcysteine regimen (20.5 hour) vs shorter intravenous acetylcysteine regimen (12 hour)

It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).

• Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
  OR 0.67 [0.11, 4.08]
  1 study · 202 participants
  Very low

Standard intravenous acetylcysteine regimen (20.5 hour) vs shorter intravenous acetylcysteine regimen (12 hour)

Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).

• Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
  OR 0.3 [0.17, 0.53]
  1 study · 217 participants
  Low

Standard intravenous acetylcysteine regimen (20.5 hour) vs shorter intravenous acetylcysteine regimen (12 hour)

Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).

• Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
  OR 0.4 [0.22, 0.75]
  1 study · 203 participants
  Low

Standard intravenous acetylcysteine regimen (20.5 hour) vs shorter intravenous acetylcysteine regimen (12 hour)

Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).

• Interventions for paracetamol (acetaminophen) overdose 2018 · Cochrane Headline outcomes only
  OR 0.39 [0.21, 0.7]
  1 study · 208 participants
  Low